Semaglutide Intermediate P29 Market Report – Research, Industry Analysis Reports and Market Demands

Global Semaglutide Intermediate P29 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Semaglutide Intermediate P29 Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 ≥99%
- 1.3.3 Others
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Semaglutide Intermediate P29 Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Oral Preparations
- 1.4.3 Injections
1.5 Global Semaglutide Intermediate P29 Market Size & Forecast
- 1.5.1 Global Semaglutide Intermediate P29 Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Semaglutide Intermediate P29 Sales Quantity (2021-2032)
- 1.5.3 Global Semaglutide Intermediate P29 Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Semaglutide Intermediate P29 by Manufacturer

3.1 Global Semaglutide Intermediate P29 Sales Quantity by Manufacturer (2021-2026)
3.2 Global Semaglutide Intermediate P29 Revenue by Manufacturer (2021-2026)
3.3 Global Semaglutide Intermediate P29 Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Semaglutide Intermediate P29 by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Semaglutide Intermediate P29 Manufacturer Market Share in 2025
- 3.4.3 Top 6 Semaglutide Intermediate P29 Manufacturer Market Share in 2025
3.5 Semaglutide Intermediate P29 Market: Overall Company Footprint Analysis
- 3.5.1 Semaglutide Intermediate P29 Market: Region Footprint
- 3.5.2 Semaglutide Intermediate P29 Market: Company Product Type Footprint
- 3.5.3 Semaglutide Intermediate P29 Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Semaglutide Intermediate P29 Market Size by Region
- 4.1.1 Global Semaglutide Intermediate P29 Sales Quantity by Region (2021-2032)
- 4.1.2 Global Semaglutide Intermediate P29 Consumption Value by Region (2021-2032)
- 4.1.3 Global Semaglutide Intermediate P29 Average Price by Region (2021-2032)
4.2 North America Semaglutide Intermediate P29 Consumption Value (2021-2032)
4.3 Europe Semaglutide Intermediate P29 Consumption Value (2021-2032)
4.4 Asia-Pacific Semaglutide Intermediate P29 Consumption Value (2021-2032)
4.5 South America Semaglutide Intermediate P29 Consumption Value (2021-2032)
4.6 Middle East & Africa Semaglutide Intermediate P29 Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
5.2 Global Semaglutide Intermediate P29 Consumption Value by Type (2021-2032)
5.3 Global Semaglutide Intermediate P29 Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
6.2 Global Semaglutide Intermediate P29 Consumption Value by Application (2021-2032)
6.3 Global Semaglutide Intermediate P29 Average Price by Application (2021-2032)

7 North America

7.1 North America Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
7.2 North America Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
7.3 North America Semaglutide Intermediate P29 Market Size by Country
- 7.3.1 North America Semaglutide Intermediate P29 Sales Quantity by Country (2021-2032)
- 7.3.2 North America Semaglutide Intermediate P29 Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
8.2 Europe Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
8.3 Europe Semaglutide Intermediate P29 Market Size by Country
- 8.3.1 Europe Semaglutide Intermediate P29 Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Semaglutide Intermediate P29 Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Semaglutide Intermediate P29 Market Size by Region
- 9.3.1 Asia-Pacific Semaglutide Intermediate P29 Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Semaglutide Intermediate P29 Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
10.2 South America Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
10.3 South America Semaglutide Intermediate P29 Market Size by Country
- 10.3.1 South America Semaglutide Intermediate P29 Sales Quantity by Country (2021-2032)
- 10.3.2 South America Semaglutide Intermediate P29 Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Semaglutide Intermediate P29 Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Semaglutide Intermediate P29 Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Semaglutide Intermediate P29 Market Size by Country
- 11.3.1 Middle East & Africa Semaglutide Intermediate P29 Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Semaglutide Intermediate P29 Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Semaglutide Intermediate P29 Market Drivers
12.2 Semaglutide Intermediate P29 Market Restraints
12.3 Semaglutide Intermediate P29 Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Semaglutide Intermediate P29 and Key Manufacturers
13.2 Manufacturing Costs Percentage of Semaglutide Intermediate P29
13.3 Semaglutide Intermediate P29 Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Semaglutide Intermediate P29 Typical Distributors
14.3 Semaglutide Intermediate P29 Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Semaglutide Intermediate P29 market size was valued at US$ 128 million in 2025 and is forecast to a readjusted size of US$ 1004 million by 2032 with a CAGR of 34.6% during review period.
Semaglutide Intermediate P29 is a key intermediate compound in the synthesis process of Semaglutide, playing an important role. Semaglutide is a GLP-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity, effectively controlling blood sugar and weight by regulating insulin secretion, suppressing appetite, and enhancing satiety. P29 undergoes several chemical reactions in the production of Semaglutide, including peptide coupling, protection/deprotection reactions, and selective functional group transformations, ultimately converting into the active drug component. With the increasing prevalence of type 2 diabetes and obesity, as well as the widespread recognition of Semaglutide’s efficacy in treating these two conditions, the market demand for Semaglutide and its intermediates continues to grow. The global demand for GLP-1 receptor agonists is increasing, driving the need for Semaglutide and its production materials, and this trend is expected to continue promoting the development of the Semaglutide industry chain.
The surge in global demand for GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Rybelsus) is directly driving increased need for semaglutide APIs and their upstream intermediates like P29 peptide. As semaglutide becomes a cornerstone therapy not only for diabetes but also for obesity, cardiovascular prevention, and potentially neurodegenerative diseases, the demand for high-purity intermediates is accelerating globally.
With oral semaglutide (Rybelsus) gaining popularity, formulation complexity has increased. This boosts the importance of highly consistent, bioactive intermediate peptides like P29. Manufacturers that can provide GMP-compliant, injectable-grade and oral-grade P29 peptides will have a competitive advantage.
China and India are emerging as key suppliers of semaglutide intermediates, especially as they scale up CDMO capabilities (Contract Development and Manufacturing Organizations). More companies are investing in fermentation-based expression systems and solid-phase synthesis automation to improve cost-efficiency and scale.
The expiration clock on Ozempic and Wegovy is ticking, prompting generic and biosimilar players (notably in India) to explore backward integration. This places P29 at the center of licensing, formulation, and IP circumvention strategies.
This report is a detailed and comprehensive analysis for global Semaglutide Intermediate P29 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Semaglutide Intermediate P29 market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2021-2032
Global Semaglutide Intermediate P29 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2021-2032
Global Semaglutide Intermediate P29 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/g), 2021-2032
Global Semaglutide Intermediate P29 market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Semaglutide Intermediate P29
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Semaglutide Intermediate P29 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zhuhai Gene-Biocon Biological Technology Co., Ltd., Vazyme International LLC, PEG-BIO Biopharm Co,.(Chongqing), Nanjing Abydos Pharma Co.,Ltd., Nanjing Hanxin Pharmaceutical Technology Co.,Ltd., Asymchem Inc., Changzhou Xuanming Pharmaceutical Technology Co., Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Semaglutide Intermediate P29 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
≥99%
Others
Market segment by Application
Oral Preparations
Injections
Major players covered
Zhuhai Gene-Biocon Biological Technology Co., Ltd.
Vazyme International LLC
PEG-BIO Biopharm Co,.(Chongqing)
Nanjing Abydos Pharma Co.,Ltd.
Nanjing Hanxin Pharmaceutical Technology Co.,Ltd.
Asymchem Inc.
Changzhou Xuanming Pharmaceutical Technology Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Semaglutide Intermediate P29 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Semaglutide Intermediate P29, with price, sales quantity, revenue, and global market share of Semaglutide Intermediate P29 from 2021 to 2026.
Chapter 3, the Semaglutide Intermediate P29 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Semaglutide Intermediate P29 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Semaglutide Intermediate P29 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Semaglutide Intermediate P29.
Chapter 14 and 15, to describe Semaglutide Intermediate P29 sales channel, distributors, customers, research findings and conclusion.

Buy now